HLS Therapeutics Inc (HLS) AI Stock Analysis

• Market Cap: C$137.60M
• Dividend Yield: N/A
• Average Volume (3M): 19.90K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.77
• Revenue Growth: 0.73%
• EPS Growth: 33.51%
• Country: CA
• Employees: 92
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.05
• Shares Outstanding: 31,273,682
• 10 Day Avg. Volume: 21,807
• 30 Day Avg. Volume: 19,898
• PEG Ratio: 0.25
• Price to Book (P/B): 1.80
• Price to Sales (P/S): 1.96
• P/FCF Ratio: 7.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: C$8.23
• Price Target Upside: 87.05% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): -0.25
• Revenue Forecast (FY): C$60.35M

• Rating: 52 Neutral
• Price Target: C$4.50 ▲(2.27% Upside)
• Action: Reiterated Date: 03/14/26
• Date: Action: Reiterated 03/14/26

The score is driven by solid cash generation and improving leverage, partially offset by persistent net losses and flat-to-down revenue trends. Technicals also remain a headwind with the stock below key moving averages and negative MACD, while valuation is limited by negative earnings and lack of dividend support. Earnings-call commentary adds some support via strong EBITDA growth and debt reduction, but tempered by softer revenue and reduced Vascepa growth expectations.

Positive Factors

Cash generation

Consistent positive operating cash flow and a surge in free cash flow in 2025 provide durable financial flexibility. This supports reinvestment in commercialization, funds working capital for launches, and enables debt reduction or strategic deals without immediate equity raises, improving resilience over the next several quarters.

Improving leverage

Material debt reduction and a lower debt-to-equity ratio reduce financial risk and interest burden, increasing operational headroom. Improved leverage strengthens the balance sheet ahead of the planned bempedoic acid launch and gives management scope to pursue targeted in-licensing or marketing investments responsibly over the next 2–6 months.

Sustained EBITDA profitability

A solid ~32% EBITDA margin and year-over-year adjusted EBITDA growth indicate the core commercial model generates operating earnings before financing and non-cash charges. This implies scalable underlying margins that can fund SG&A and launches, improving medium-term cash translation if below-EBIT items are managed.

Negative Factors

Persistent net losses

Ongoing net losses and negative ROE signal the company has not yet converted operating strength into bottom-line profitability. This constrains retained earnings, limits ability to reward shareholders, and increases reliance on cash flow or financing to fund growth, posing a medium-term earnings risk if cost items below EBITDA persist.

Weak top-line trend

Flat-to-declining revenue trends restrict operating leverage and the capacity to expand margins sustainably. With recent year-over-year revenue softness and guidance trimming in key products, consistent top-line weakness could limit funding for launches and reduce long-term growth visibility absent successful new product rollouts.

Business model & concentration risks

Dependence on in-licensed products, third-party manufacturing, and a small product base concentrates execution risk. Competitive pressure on Clozaril and moderated Vascepa growth expectations show sensitivity to payor competition and inventory cycles, raising sustainability concerns if new launches or partnerships do not offset declines.

HLS Therapeutics Inc Business Overview & Revenue Model

Company Description

HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular (CV) markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic used in the treatment of schizophrenia; Vascepa, an icosapent ethyl capsules; and PERSERIS, an injectable risperidone product for the treatment of schizophrenia. It also offers MyCare psychiatry lab assays and MyCare Insite point of care therapeutic drug-level monitoring tests. In addition, the company holds the U.S. marketing rights of Absorica, a commercial stage dermatology product; Canadian rights of Trinomia for CV therapeutics; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. was founded in 2018 and is headquartered in Etobicoke, Canada.

How the Company Makes Money

HLS primarily makes money by generating net product sales from prescription medicines it commercializes in its target markets (Canada and, for certain products, the United States). Revenue is driven by (1) sales volume (prescriptions filled and units sold) and (2) net realized price after customary deductions such as wholesaler and pharmacy discounts, chargebacks, rebates to public and private drug plans, patient support/copay programs, returns, and distribution/service fees. The company’s business model centers on in-licensing or acquiring rights to established or late-stage products and then monetizing those rights through commercialization: building medical and sales capabilities, negotiating formulary access with payors, operating patient support programs, and managing the supply chain. Where HLS has partnered with other companies for product rights or commercialization arrangements, its earnings can be affected by contractual obligations such as royalties, profit-sharing, milestone payments, and supply/transfer pricing terms; specific counterparties and product-by-product terms are not available in this response and are therefore null.

HLS Therapeutics Inc Financial Statement Overview

Summary

Cash flow is a notable strength (consistently positive operating cash flow and a sharp free-cash-flow improvement in 2025) and leverage has improved with declining debt-to-equity. Offsetting this, revenue has been broadly flat and the company remains net loss-making with weak operating profitability below EBITDA, keeping overall fundamentals mixed.

Income Statement

Revenue has been broadly flat over the last several years (2025 annual up slightly, following a decline in 2024), and profitability remains challenged with net losses every year provided. A key positive is sustained EBITDA profitability with a solid 2025 annual EBITDA margin (~32%) and improvement versus 2023, suggesting the core business can generate operating earnings before non-cash/financing items. However, operating profitability is still weak (negative EBIT margin in recent years) and net margin remains meaningfully negative in 2025, indicating ongoing pressure from costs below EBITDA (e.g., depreciation/amortization, interest, or other items).

Balance Sheet

Leverage looks manageable-to-moderate with debt-to-equity improving in 2025 (~0.81) versus 2024 (~0.93), supported by a sizable equity base. Total debt has also trended down materially from 2020–2022 levels, which reduces financial risk. The main weakness is continued negative returns on equity (still negative in 2025), consistent with ongoing net losses and indicating that shareholder capital is not yet generating positive bottom-line returns.

Cash Flow

Cash generation is a clear strength: operating cash flow has been consistently positive across all years shown and improved notably in 2025 versus 2024. Free cash flow is also positive in most years and surged in 2025, showing better cash conversion and financial flexibility. The primary concern is volatility—2020 saw deeply negative free cash flow—and despite strong cash flow, the business still reports net losses, implying cash performance may not fully translate into sustainable earnings power yet.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	56.47M	56.62M	63.07M	61.47M	60.01M
Gross Profit	24.01M	47.62M	55.45M	56.49M	56.04M
EBITDA	18.02M	17.22M	12.88M	18.00M	25.41M
Net Income	-12.65M	-19.66M	-27.53M	-23.60M	-13.12M
Balance Sheet
Total Assets	137.28M	159.90M	209.06M	241.65M	275.90M
Cash, Cash Equivalents and Short-Term Investments	11.70M	17.46M	21.95M	20.72M	21.18M
Total Debt	49.73M	66.45M	87.62M	97.34M	97.57M
Total Liabilities	75.72M	88.56M	111.36M	116.33M	115.17M
Stockholders Equity	61.56M	71.34M	97.70M	125.32M	160.74M
Cash Flow
Free Cash Flow	15.81M	7.99M	15.60M	6.79M	11.92M
Operating Cash Flow	16.02M	8.00M	15.79M	16.94M	16.43M
Investing Cash Flow	-1.73M	11.73M	-189.00K	-10.15M	-4.51M
Financing Cash Flow	-20.52M	-23.36M	-14.64M	-6.86M	-11.40M

HLS Therapeutics Inc Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 4.40
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:HLS, the sentiment is Negative. The current price of 4.4 is below the 20-day moving average (MA) of 4.42, below the 50-day MA of 4.52, and below the 200-day MA of 4.99, indicating a bearish trend. The MACD of -0.04 indicates Negative momentum. The RSI at 43.34 is Neutral, neither overbought nor oversold. The STOCH value of 82.22 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:HLS.

HLS Therapeutics Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RX	80 Outperform	C$176.15M	12.11	23.25%	1.60%	22.22%	25.50%
CPH	78 Outperform	C$418.91M	10.05	24.23%	―	94.28%	5.23%
GUD	71 Outperform	C$628.40M	-38.64	-0.45%	―	18.70%	88.31%
MDP	68 Neutral	C$98.52M	211.50	0.87%	―	2.14%	-83.06%
HLS	52 Neutral	C$137.60M	-8.75	-19.40%	―	0.73%	33.51%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AQS	38 Underperform	C$663.17K	0.45	9.47%	―	122.30%	75.74%

HLS Therapeutics Inc Corporate Events

HLS Therapeutics Lifts Profitability, Cuts Debt as It Expands Cardiovascular Portfolio

HLS Therapeutics reported fiscal 2025 revenue of $55.5 million, with Adjusted EBITDA rising 18% to $19.6 million and cash from operations more than doubling to $17.1 million. The company cut operating expenses, reduced long-term debt by 26%, and lowered annual interest costs by 43% through a new credit facility.

Canadian product sales grew modestly in local currency, while U.S. Clozaril declines slowed, aided by a specialty pharmacy program, and Vascepa turned profitable for the full year. HLS expanded its cardiovascular portfolio by in-licensing NILEMDO and NEXLIZET for Canada, with NILEMDO now approved and available, and signalled that near-term guidance reflects launch investments ahead of expected stronger growth from these products after 2026.

Management projects 2026 revenue of $56 million to $60 million and Adjusted EBITDA of $18.5 million to $21 million, anticipating mid-single-digit top-line growth and roughly flat earnings due to NILEMDO launch costs. With a strengthened balance sheet and additional financial flexibility, the company plans to leverage its stable base business and new cardiovascular assets to drive sustained profitable growth and potentially expand its portfolio further.

The most recent analyst rating on (TSE:HLS) stock is a Hold with a C$4.75 price target. To see the full list of analyst forecasts on HLS Therapeutics Inc stock, see the TSE:HLS Stock Forecast page.

HLS Therapeutics launches NILEMDO in Canada to tackle unmet cholesterol treatment needs

HLS Therapeutics has launched NILEMDO (bempedoic acid) across Canada, offering a first-in-class, once-daily oral non-statin therapy for adults who cannot reach LDL-cholesterol targets on existing treatments or are statin intolerant. Supported by the large CLEAR Outcomes trial, the drug demonstrated a reduction in major adverse cardiovascular events and is estimated by HLS to address an unmet need in more than half a million Canadians at risk of cardiovascular disease.

The company expects meaningful private insurance coverage for NILEMDO starting in the second quarter of 2026, with potential public reimbursement later in the year, which could enhance access and strengthen its cardiovascular franchise. Alongside Vascepa and the ongoing regulatory push for the combination pill NEXLIZET, the launch positions HLS as a leading provider of novel oral cardiovascular therapies in Canada and may improve treatment options and outcomes for high-risk patients.

The most recent analyst rating on (TSE:HLS) stock is a Hold with a C$4.75 price target. To see the full list of analyst forecasts on HLS Therapeutics Inc stock, see the TSE:HLS Stock Forecast page.

HLS Therapeutics launches NILEMDO in Canada to target unmet LDL-cholesterol needs

HLS Therapeutics has launched NILEMDO, a once-daily oral non-statin therapy, across Canada for adults who cannot reach LDL-cholesterol targets with current treatments or who are statin intolerant. The drug, in-licensed from Esperion Therapeutics and approved by Health Canada in late 2025, expands HLS’s cardiovascular portfolio alongside Vascepa and is aimed at a sizeable patient population estimated at more than half a million Canadians.

NILEMDO leverages a novel mechanism that lowers LDL-C with a lower likelihood of muscle-related side effects and can be used alone or with statins, ezetimibe, or PCSK9 inhibitors, fitting into existing treatment regimens. Its approval is backed by the large CLEAR Outcomes trial showing significant reductions in major adverse cardiovascular events, while reimbursement submissions are underway with expectations for private coverage this year and potential public reimbursement in 2026, and HLS is also progressing NEXLIZET, a bempedoic acid and ezetimibe combination pill, toward a targeted 2027 Canadian launch.

These developments underscore HLS’s push to become a leader in oral cardiovascular therapies in Canada and may materially improve treatment options and cardiovascular risk management for high-risk patients who have struggled to meet guideline-recommended LDL-C goals. The addition of NILEMDO and the anticipated arrival of NEXLIZET could enhance the company’s competitive standing and broaden access to evidence-backed, non-statin lipid-lowering options for Canadian patients and clinicians.

The most recent analyst rating on (TSE:HLS) stock is a Hold with a C$4.75 price target. To see the full list of analyst forecasts on HLS Therapeutics Inc stock, see the TSE:HLS Stock Forecast page.

HLS Therapeutics Sets March 12 Date for Fiscal 2025 Results and Investor Call

HLS Therapeutics Inc. will release its fiscal 2025 fourth-quarter and full-year financial results on March 12, 2026, before markets open, and will host a conference call at 8:30 a.m. ET the same day, led by its CEO, CFO, and Chief Commercial Officer, with accompanying slides available via webcast. The scheduled results release and investor call underscore the company’s ongoing effort to engage capital markets and provide transparency around its performance as it advances its portfolio of psychiatric and cardiovascular treatments in North America.

A live audio webcast, traditional dial-in options, and a RapidConnect link will be available for investors and analysts to access the call, with a taped replay offered for seven days and an archived webcast for one year. By making multiple access channels and extended replay options available, HLS is facilitating broad stakeholder access to its financial disclosures, which may help support liquidity in its shares and maintain interest from the investment community.

The most recent analyst rating on (TSE:HLS) stock is a Hold with a C$4.75 price target. To see the full list of analyst forecasts on HLS Therapeutics Inc stock, see the TSE:HLS Stock Forecast page.